Investor AB holds a concentrated book of 7 reported positions worth $14.4B as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). The SEC 13F shows only Investor AB's US-listed positions. Its main portfolio is mostly Stockholm-listed and does not appear in this book. This quarter they opened Micron Technology Inc. Their largest long position is AstraZeneca PLC at 68% of the reported non-option book.
Top-heavy: concentrated book
Excluding AstraZeneca PLC (68% of the book), the rest is a concentrated book:
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
+3 sectors below the cut, under 0.5% together
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Investor AB
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Evelyn Partners Group Ltd | 4 / 7 | $41.6B |
| Credit Capital Investments LLC | 2 / 7 | $73.5M |
| Rakuten Securities, Inc. | 5 / 7 | $99.3M |
| Channing Global Advisors, LLC | 2 / 7 | $39.4M |
| Prudential PLC | 4 / 7 | $3.4B |
| Certuity, LLC | 4 / 7 | $325.6M |
| Intesa Sanpaolo S.p.A. | 3 / 7 | $246.6M |
| Asset Management Advisors, LLC | 2 / 7 | $25.4M |
Ranked by the share of each fund's own book sitting in the names it shares with Investor AB: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | AstraZeneca PLC ORD | $9.8B | 51.59M | 67.9% | —Held | |
| 2 | Nasdaq Inc COM | $4.6B | 58.44M | 32.0% | ▲+0.1% Added · +57K sh | |
| 3 | Mediwound Ltd SHS NEW | $12.8M | 872.1K | 0.1% | —Held | |
| 4 | Cellebrite Di Ltd ORDINARY SHARES | $1.1M | 75.0K | <0.1% | ▲+36% Added · +20K sh | |
| 5 | Micron Technology Inc COM | $543K | 470 | <0.1% | ▲New New position | |
| 6 | Verizon Communications Inc COM | $478K | 11.3K | <0.1% | —Held | |
| 7 | Biomarin Pharmaceutical Inc COM | $212K | 3.7K | <0.1% | —Held |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/889232/holdings"
Use Arkolith to show INVESTOR AB's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 14, 2026 | 45d | 7 | $14.4B | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 45d | 10 | $15.1B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 48d | 12 | $5.7B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 45d | 12 | $5.2B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 45d | 13 | $5.2B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 45d | 13 | $4.4B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 45d | 8 | $4.5B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 45d | 7 | $4.3B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 45d | 6 | $3.5B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 45d | 10 | $3.7B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 45d | 10 | $3.4B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 45d | 9 | $2.8B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 45d | 9 | $2.9B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 45d | 7 | $3.2B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 45d | 5 | $3.6B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 45d | 7 | $3.3B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 46d | 5 | $3.0B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 46d | 8 | $3.5B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 45d | 7 | $4.1B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 46d | 4 | $3.7B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 47d | 3 | $3.4B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 47d | 2 | $2.9B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 47d | 3 | $2.6B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 47d | 7 | $2.4B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.